摘要
目的:探讨二次电切联合吡柔比星即刻灌注治疗非肌层浸润性膀胱癌临床治疗效果。方法:回顾2010年1月~2014年5月诊断为非肌层浸润性膀胱癌共63例患者,分为对照组和观察组,其中拒绝行二次TURBT患者28例作为对照组,行二次TURBT治疗患者35例作为观察组。所有病例均于术后即刻行吡柔比星灌注治疗。对比两组患者6、12、18、24个月肿瘤复发率及进展率。结果:一次电切患者6、12、18、24个月肿瘤复发率、进展率分别为:10.7%、0;17.9%、3.6%;28.6%、10.7%;46.4%、21.4%。二次电切患者6、12、18、24个月肿瘤复发率及进展率分别为2.9%、0;2.9%、0;8.6%、2.9%;14.3%,5.7%,差异有统计学意义(均P<0.01)。结论:TURBT术后即刻行膀胱灌注化疗,能显著降低非肌层浸性膀胱癌的复发率,二次电切对于彻底清除非肌层浸润性膀胱残余肿瘤、减少其复发率及进展率有十分重要的意义,有助于临床医生选择正确的后续治疗方案和提高患者的生存率。
Objective:To evaluate the clinical efficacy of immediate intravesical instillation of second resection combined with pirarubicin in the treatment of non-muscular invasive bladder carcinoma(NMIBC).Methods:Sixtythree cases of NMIBC from Jan.2010 to May 2014 were reviewed.The patients who received second resection of transurethral resection of bladder tumor(TURBT)served as treatment group(35 cases),and the rest 28 cases given only one resection as control group.All of the patients were treated with immediate intravesical instillation with pirarubicin.Recurrence and progression between the two groups were observed at 6 th,12 th,18 th and 24 th month.Results:At 6 th,12 th,18 th and 24 th month,the recurrence rate and the progression rate had statistically significant difference between treatment group and control group(P<0.01)(for control group:10.7% and 0,17.9% and 3.6%,28.6% and 10.7%,and 46.4% and 21.4% respectively;for treatment group:2.9% and 0,2.9% and 0,8.6% and 2.9%,and 14.3% and 5.7%respectively).Conclusions:Immediate intravesical instillation of pirarubicin after TURBT can significantly can significantly reduce the relapse of NMIBC.Second resection was effective for removing the remnant tumors of NMIBC and also helped clinicians choose the right treatment strategies and improve the survival of patients with NMIBC.
出处
《微创泌尿外科杂志》
2018年第1期61-64,共4页
Journal of Minimally Invasive Urology
关键词
二次电切
非肌层浸润性膀胱癌
肿瘤复发
局部
即刻灌注
吡柔比星
second resection
non-muscle invasive bladder urothelial carcinoma
neoplasm recurrence
local
immediate intravesical instillation
pirarubicin
